PDS Biotechnology (NASDAQ:PDSB – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.06, FiscalAI reports.
Here are the key takeaways from PDS Biotechnology’s conference call:
- The company amended VERSATILE-003 to make PFS an earlier interim primary endpoint after the FDA raised no objections, aiming to shorten trial duration and enable a potential accelerated approval with a PFS readout expected in about 1–1.5 years.
- Final VERSATILE-002 topline showed a median overall survival of 39.3 months in PD-L1 CPS ≥1 patients, which management cites as robust evidence supporting the phase III amendment and durable clinical benefit.
- Early NCI-led data for PDS-01ADC plus docetaxel in metastatic castration-resistant prostate cancer reported a median PFS of 9.6 months and a median PSA decline of 40% (6 of 16 patients >50% PSA decline), reinforcing the program’s potential across solid tumors.
- The company secured new U.S. and Japanese patents for PDS0101 and expects biologics exclusivity, which together extend market protection into the 2040s and strengthen the intellectual property estate.
- Financially, PDS reported a 2025 net loss of $34.5 million and held $26.7 million in cash at year-end, a level that may pressure runway and necessitate additional financing.
PDS Biotechnology Price Performance
Shares of NASDAQ:PDSB opened at $0.61 on Wednesday. PDS Biotechnology has a one year low of $0.51 and a one year high of $1.92. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.09 and a quick ratio of 2.09. The company has a market cap of $31.68 million, a price-to-earnings ratio of -0.81 and a beta of 1.20. The firm has a 50 day simple moving average of $0.70 and a 200 day simple moving average of $0.85.
Analyst Ratings Changes
Check Out Our Latest Stock Report on PDS Biotechnology
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of PDSB. Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology during the 4th quarter valued at $25,000. Marshall Wace LLP acquired a new position in PDS Biotechnology in the 2nd quarter worth about $91,000. Jane Street Group LLC bought a new position in PDS Biotechnology in the second quarter valued at about $92,000. Susquehanna International Group LLP boosted its stake in shares of PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in shares of PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares in the last quarter. 26.84% of the stock is currently owned by institutional investors.
PDS Biotechnology Company Profile
PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.
Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.
See Also
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
